The aim of this study was to characterize the type and degree of discrepancies between non-expert and expert diagnoses of CNS tumors to identify the value of consultations in surgical neuropathology. Neuropathology experts from 5 National Comprehensive Cancer Network (NCCN) member institutions participated in the review of 1281 consultations selected based on inclusion criteria. The consultation cases were re-reviewed at the NCCN headquarters to determine concordance with the original diagnoses. Among all consultations, 249 (19.4%) were submitted for expert diagnoses without final diagnoses from the submitting institution. Within the remaining 1032 patients, the serious/major discrepancy rate was 4.8%, and less serious and minor discrepancies were seen in 19.4% of the cases. The discrepancy rate was higher among patients who were referred to NCCN institutions for consultation compared to those who were referred for treatment only. The discrepancy rates, patient demographics, type of consultations and submitting institutions varied among participating NCCN institutions. Expert consultations identified a subset of cases with significant diagnostic discrepancies, and constituted the initial diagnoses in some cases. These data indicate that expert consultations in glial tumors and all types of pediatric CNS tumors can improve accurate diagnosis and enable appropriate management.
INTRODUCTION
Neuropathology is a subspecialty of pathology recognized with certification by the American Board of Pathology; such certification requires a minimum of 2 years of accredited training (1) . There are 33 accredited neuropathology training programs (https://apps.acgme.org/ads/public) as of January 2016, and there is an average of 35 first year fellows/trainees in the United States at any given year. As of 2016, nearly 30 states do not have an accredited neuropathology training program within their borders. Furthermore, in many anatomic pathology residency training programs, neoplastic neuropathology material and expertise may be limited to provide confident diagnostic competence for the graduates. Such programs often seek help from affiliated institutions or other programs to fulfill their educational objectives.
The majority of non-academic pathology departments, particularly those outside the large university systems or healthcare networks, may not have a board-certified neuropathologist among their staff. This is understandable because the limited number of neuropathology specimens often does not justify employing a full-time neuropathologist, and such organizations often do not have educational or research programs in neuropathology. In these circumstances, the cases are often diagnosed by one or more of the members of the department with special interest in neuropathology or sent to experts for initial diagnosis or consultation.
In addition to the rarity of neuropathologists and the rarity of cases in most laboratories, the necessity for specialized analyses and the need for close and continuous interaction with clinical colleagues in neurological specialties challenge the pathologists in terms of reaching the correct diagnosis. Many pathology departments address this issue through consultations from experts outside their institution.
The decision to seek consultation is often a subjective process that depends on the specific circumstances of the institution, the patient and the medical staff. The tightening of the US healthcare budget at all levels and the pressure to spend less for more services may force many institutions to curtail their out-of-hospital expenses. This often results in attempts to reduce the number of cases sent for consultations (2, 3) . Hospital administrations may be reluctant to promote or approve outside consultations because these activities are not always completely reimbursed to the requesting institution by third parties; and in many instances, administrators cannot accurately identify which practice would be more costefficient and risk-averse.
All of the above circumstances are limiting in terms of providing accurate and state-of-the-art diagnoses, particularly for CNS neoplasms (4-7). The reluctance to generate outside consultations is challenged by the studies that underscore the value and necessity of consultations (7, 8) . These studies promote consultation as a quality assurance measure to reduce errors and ensure appropriate treatment (6, (9) (10) (11) (12) . The importance of obtaining consultations has been further underlined by studies that identify significant discrepancies between nonexpert and expert diagnoses (13, 14) . Consultations often lead to changes in diagnoses for a small percentage of patients, directing care more appropriately and with more value for the health care dollars spent (13) . The appropriate use of consultations not only complies with the current standards of care, but also provides a positive feedback and training to pathologists who are not experts in this field. However, choosing which case to send for consultations has never been an easy question, and there are no universally applicable standards in deciding whether a case needs to be sent for consultation.
The argument for the positive impact of expert neuropathology consultations (as in all areas of pathology) can be made stronger if best practices and realistic guidelines can be formulated to improve patient care (9, 13) . In order to provide a more comprehensive perspective and to help identify certain recommendations for surgical neuropathology consultation practice, we conducted a multi-center analysis of brain and spinal cord neoplastic surgical specimens that were reviewed at 5 NCI-designated comprehensive cancer centers under the auspices of the National Comprehensive Cancer Network (NCCN). The participating tumor neuropathology experts critically reviewed consultations performed at their institutions, and these were analyzed further in detail at the NCCN headquarters. Our aim was to identify trends in consultation practices, the type and degree of discrepancies and to propose, to the best of our ability, certain recommendations for requesting and performing such consultations.
MATERIALS AND METHODS

Patients
One thousand five hundred consecutive neuropathology consultation cases submitted to 5 participating NCCN member institutions over a period of approximately 6 months were reviewed for eligibility. The initial set of cases was identified by expert neuropathologists who participated in the study from the 5 NCCN member Institutions (Institutions #1 through #5). Each NCCN member institution enrolled a total of 300 consecutive consultation cases and submitted them to the principal investigator (JMB). The inclusion criteria were identified as follows: (1) pathology material obtained in an outside institution from patients undergoing brain and spinal cord biopsy and submitted for consultation to a participating NCCN institution; (2) consultation material with sufficient tissue to allow a diagnostic opinion and availability of sufficient information required for the study; and (3) pathology material reviewed by one of the participating consultant neuropathologists with completion of the institutional data collection form. Exclusion criteria included (1) patients whose material and/or original diagnosis was rendered by another NCCN member institution participating in the study, and cases that were reviewed by more than 1 NCCN member institution at any time, and (2) cases with insufficient material or clinical information. Appropriate institutional review board permissions were obtained separately in each participating institution. Privacy and security of the protected health information was maintained by the principal investigators and the NCCN headquarters.
An eligibility log was maintained at each NCCN member institution and list of all cases were screened for the study. The data elements collected for each case are presented in Table 1 . The NCCN headquarters required each participating NCCN member institution to submit their eligibility log with the following information: (1) NCCN case number and (2) eligibility status. The institutional data elements for the CNS diagnostic accuracy study include limited demographic and treatment information and diagnostic information. The categories of institutional data collected by each NCCN Member Institution are summarized and the individual elements are retained in the data dictionary.
Institutional Data Collection
At each participating institution, cases were given a unique sequential number as they were entered into the study. Institutional data elements (outlined in the CNS diagnostic accuracy study data dictionary) were collected through pathology review at each NCCN member institution after the expert neuropathologist has made a diagnosis. The expert neuropathologists who participated in the study have recorded the data on the institutional data collection forms following a diagnosis.
Institutional Data Submission Process
Institutional data were submitted to the NCCN headquarters at Fort Washington, PA via secure fax or e-mail. The de-identified records were entered and maintained in a secure and confidential database in a centralized, aggregate database. The NCCN's CNS diagnostic accuracy study database application was designed with multiple security features. Rolebased permissions were applied at both levels to limit data access and application functionality where applicable.
Central Review and Data Entry
Because the forms were coded at NCCN, the institution name and location were used to determine the type of the original submitting institution (academic center, community hospital-large or small, and others such as private practice or undetermined). Once all cases from all institutions were received by NCCN headquarters, collection of cases was stopped; each case was ascertained for inclusion and exclusion criteria, and the data from submitted cases were extracted and coded for further analysis. All forms were recorded in the database and all cases in which the text of the original did not exactly match the text of the NCCN diagnosis were selected for the review by the principal investigator. All others in which the original text exactly matched the consultant's diagnoses were considered to be 'in agreement' and were coded as having "no discrepancy". The cases in which the texts did not exactly match were further entered into a database for classification as to presence/absence of disagreement and the level of disagreement ( Table 2 ). The level of disagreement was interpreted as having "No Discrepancy" if the tumor type and grade were the same but there was inconsequential change in the wording of the final diagnoses. The cases in which there was an addition or deletion of information (e.g., a change in the histological pattern) but no change in tumor type and grade were considered as having "Minor Discrepancy." Diagnoses that were significantly different, but did not significantly alter patient care or necessitate change of treatment (e.g., change from oligoastrocytoma grade II to oligodendroglioma grade II) were considered "Less Serious." All discrepancies in which there was a major change in histological type or grade that was sufficient to alter patient management were deemed "Serious/Major Discrepancy." Twelve reasons could be ascribed to any case for disagreement with the referring institution (Table 2 ). Diagnoses were also coded into 6 broad categories for statistical review (Table 3) .
Statistical Analysis
Institutional data were submitted to the NCCN for statistical analysis. All analyses were performed by one of the authors (T.A.). These consisted mainly of cross tabulations of patient characteristics with NCCN member institution and of these with the concordance results. Chi-square tests of association were provided where appropriate.
RESULTS
A total of 1281 cases from the submitted group fulfilled the criteria and were included in the study. The rate of serious/ major discrepancies was 4.1% among female (n ¼ 19) patients and 5.4% among male patients (n ¼ 31), which was slightly disproportionate to the female to male ratio (1:1.2); however, the total number of serious/major discrepancy was not sufficiently large to consider this difference significant.
A total of 249 cases (19.4%) were submitted to the NCCN institutions without a primary final diagnosis; and the submitting pathologist relied on the diagnoses of the NCCN institution for the final report. These cases were similar to all reviewed cases in terms of age distribution (median age 53 vs 49 for the whole group), but had a slightly higher female/male ratio (0.97 vs 0.78 among those with original diagnoses). Among the 249 patients without original diagnosis, NCCN institutions #1, #2, #3, and #5 had 75%-90% of cases submitted for consultation only, while institution #4 had 100% of such cases submitted for further treatment.
The concordance of the diagnoses could be evaluated in the remaining 1032 cases. As expected, there was a lower percentage of cases from academic centers that were referred for initial diagnosis. The observed rate of serious/major discrepancy was slightly higher among pediatric patients, but this did not reach significance (age <16; 7.0% vs 4.5%; p ¼ 0.1974). Table 4 shows the patient demographic and baseline The female/male ratio was similar in each NCCN institution. Among the 1032 eligible patients with an original diagnosis, 760 patients were referred to NCCN institutions for further treatment, and 272 were submitted for second opinion or consultation only. Among the 5 NCCN institutions, there was a significant difference in terms of referral type (p < 0.0001); institution #5 had 88% of the patients for consultation only, while this number ranged from 0% to 40% for other institutions. Nearly 56% of all cases were from small or large community hospitals, while consultations from academic centers were in the range of 20% for all NCCN institutions.
Among the 12 possible coded reasons for disagreement, all cases had 1 or 2 codes, and these codes are listed in Table 2 . The level of disagreement by NCCN institutions is presented in Tables 5 and 6 , based on the type of referring institution. Among the NCCN institutions, site #5 had a slightly higher rate among serious/major discrepancies (10.9% vs 4.8% for the whole group) as well as in the "less serious discrepancy" category (24.5% vs 15.4% for the whole group), while "no discrepancy" rate was much lower (59.4 vs 75.2 for the whole group). This may be partly related to the high percentage of "consultation only" cases for that institution. Other institutions had rates closer to the group mean values. Institution #5 also had the lowest number of referrals from academic centers and large community hospitals (32.8% vs. 51% for the whole group; p < 0.0001).
The levels of disagreement among pediatric cases compared to adult cases were slightly higher (7% vs 4.5%) but the disagreement levels did not differ among NCCN institutions and were not affected by the type of referring institution. The concordance of diagnoses was 75% in both pediatric and adult cases; the remaining cases had some level of discrepancy. Other levels of discrepancies were similar among pediatric and adult patients. There was no difference in disagreement categories in terms of patient sex. Likewise, the overall percentages within each category of disagreement were similar among referring hospital type.
The characteristics of the 50 cases in which the discrepancy was considered to be serious are listed in Table 7 . Among these, the most common diagnosis was glial tumor (35 cases; 70%). Thirty-one cases were given a different histological type and grade based on the current World Health Organization (WHO) classification scheme. Interestingly, we found no cases in which a malignant tumor diagnosis was revised to a benign entity. On the other hand, a few cases of nonneoplastic diagnoses were revised to a neoplastic category, and similar number of low-grade tumor diagnoses was changed to non-neoplastic entities. Among 21 patients with an original diagnosis of metastatic tumor there were 2 minor/less serious and 2 major discrepancies, and 2 classified as "other." Among the 1032 patients with an original diagnosis, 776 (75.2%) had no discrepancy. In short, 209 (20.3%) diagnoses had less serious to serious discrepancies, and 249 relied on the diagnosis of NCCN experts, for a total of 458 (35.7%) patients being potentially helped by the NCCN consultation process.
DISCUSSION
Previous studies have shown variable rates of serious discrepancies in original diagnosis of surgical pathology specimens, and most studies suggest a rate of 5% for serious discrepancies (15); our findings reflect a similar trend. This is somewhat different from one earlier study involving neuropathological specimens that suggested a rate of serious discrepancy around 3.7% (14) . This may be partially related to the fact that the study included only 1 referral institution, adult patients, and only gliomas. On the other hand, a separate study found the serious discrepancy rate to be 8.8% (13) . This study included a more diverse group of material as well as age groups, and reflected a more realistic distribution of diagnostic categories and patient characteristics. Several findings have been described previously and may need to be reiterated here: first, the rate of discrepancies among pediatric cases, and second, the challenges in the categorization of tumors in the glioma category. Pediatric neoplasms have always been challenging even to the most experienced neuropathologists; and the divergence of histological patterns and immunohistochemical profiles of pediatric neoplasms can cause significant diagnostic discrepancies. Pediatric tumors are more increasingly being evaluated in the light of molecular features, and the lack of such analytical tools in a laboratory may also be a factor in misclassification or incomplete final diagnosis. Pediatric CNS tumors also pose a challenge to the surgical pathologist due to their rarity in routine practice; even specialized hospitals receive an average of 100-150 new cases annually. It is difficult to gain experience on these tumors for many surgical pathologists if they are not dedicated to review all institutional cases. Given all the reasons above, we believe it is critical to submit most (if not all) pediatric CNS tumors for expert consultants with sufficient experience and analytical tools for accurate characterization of these neoplasms.
The current WHO classification scheme relies on a number of molecular alterations in gliomas as well as in embryonal tumors, and the availability of these analytical tools (eg, specialized immunohistochemical studies) is paramount to correct classification (16) . Even though this study was conducted prior to the release of the current 2016 WHO scheme, many of the markers now considered standard of care, were already being used in NCCN referral institutions for some time. The availability of such tools has accounted for some of the discrepancies in the diagnosis of gliomas.
A further challenging issue is the accurate grading and histological typing of gliomas. This topic has been quite challenging, and diagnostic categories such as oligoastrocytomas have been notorious for their lack of uniform diagnostic criteria that causes significant discrepancies even among experts (17) . Similarly, many studies on diagnostic discrepancies among CNS tumors identify gliomas as one of the tumor groups with the most frequent problems (9, 13, 14) . This challenge is partly due to the loose criteria for some tumor types, and limited criteria for the designation of tumor grade within some gliomas. In addition, recognition of the challenges in sampling, and the ability to correlate clinical/radiological information with the pathological findings gives an advantage to the expert neuropathologist, and often accounts for some of the discrepancies seen in this group of tumors. Finally, the ability to perform special stains and molecular analysis such as IDH1 or H3.3 K27M immunohistochemical stains (which have been available in NCCN referral institutions in recent years) also imparts a greater advantage to the consultant neuropathologist to reach the correct diagnosis. This issue is expected to become more complex and much more prominent in the near future with the adoption of new terminology that is predicated on performing some of these specialized analyses (16) .
Expert diagnoses have often been considered a tool for improving patient care through a collaborative consultation process that enables a more accurate and realistic interpretation of pathological specimens. While this common sense impression is readily recognized by everyone, practical considerations often intervene and may prevent pathologists to refer every case for consultation. Therefore, it becomes critical to review each discipline to identify the specific areas of weaknesses and strengths in general surgical pathology practice. Our study confirms the overall rate of discrepancies and the general challenges in the diagnosis of CNS tumors, and identifies 2 key areas in which an expert neuropathologist's help is strongly recommended. These 2 areas are neoplasms in the pediatric age group as well as glial tumors, particularly those that appear to be low grade or ambiguous in histological type. We also identify consultation practice as a "first line of defense" in a significant number of cases. We expect that the advancing technology, increased use of virtual microscopy and more efficient electronic communications are likely to ease the requisition and performance of consultations, hopefully leading to better patient care for all patients with CNS tumors. 
